#United States #Creatv Bio #PD-L1 Test #Metastatic Breast Cancer #Monmouth Junction

Revolutionary Blood Test for PD-L1 and Its Implications in Cancer Treatment

In a remarkable advancement in cancer treatment monitoring, researchers from Creatv Bio, a division of Creatv MicroTech, Inc. located in Monmouth Junction, New Jersey, in collaboration with The Mayo Clinic in Jacksonville, Florida, and BriaCell Therapeutics Corporation from Philadelphia, Pennsylvania, have made significant strides in understanding the dynamics of immunotherapy in metastatic breast cancer (mBC) patients. Their study suggests that the PD-L1 expression, a crucial biomarker for assessing the effectiveness of treatments, can be evaluated through a blood test utilizing the LifeTracDx® technology.

The findings were presented at the renowned San Antonio Breast Cancer Symposium (SABCS) in December 2024 and are detailed in a study titled PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis. The LifeTracDx® test is designed to isolate circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs) that express PD-L1, providing an innovative approach to monitoring the tumor’s response to therapy at a cellular level.

Study Highlights

The clinical trial involved 36 patients undergoing treatment with the SV-BR-1-GM vaccine alongside an immunotherapy drug, Retifanlimab. The analysis revealed compelling results: a decrease in both CTCs and CAMLs was significantly correlated with improved progression-free survival (PFS) rates. Furthermore, among the patients receiving the SV-BR-1-GM therapy, 15 exhibited increased PD-L1 expression, which was linked to enhanced responses when combined with the anti-PD-L1 checkpoint inhibitor.

This groundbreaking data suggests that real-time monitoring of PD-L1 can predict treatment responses, enabling healthcare providers to tailor therapies more efficiently and potentially improve outcomes for patients battling metastatic breast cancer. The LifeTracDx® technology not only focuses on the expression of PD-L1 but also serves as a companion diagnostic tool for a variety of tumor markers, emphasizing its versatility in cancer management.

The Role of LifeTracDx®

By employing LifeTracDx®, researchers can analyze the cellular components derived from the bloodstream, including CAMLs, which are macrophages that have ingested tumor cells. This innovative technique allows for a detailed overview of the tumor's biology, important for understanding disease progression and treatment efficacy. With applications ranging from predicting responses to clinical therapies within as little as 30 days to early detection of cancer recurrence, LifeTracDx® stands at the forefront of aiding oncologists in their battle against cancer.

Conclusion

Creatv Bio continues to push the frontier of cancer diagnostics through its commitment to innovation and research. As the results of the study at SABCS illustrate, the PD-L1 measured by blood tests provides an essential tool in the arsenal against metastatic breast cancer. Creatv Bio is serving not only the immediate needs of patients but also contributing significantly to the broader landscape of cancer research and treatment methodologies. As more insights emerge from ongoing research and clinical trials, the hope for personalized and effective cancer treatments grows ever closer to reality.

For more information about Creatv Bio and its innovative diagnostics, their resources can be explored at www.creatvbio.com.